KLUS Pharma will attend BIO Partnering at JPM on Jan 11-15. Introduction and new updates are expected for several programs that are under development or co-development with the parent company Kelun-Biotech, including JAK inhibitor, HER2 ADC, HBV therapeutics, and biological anti-coagulant.
Potential partners with strong clinical and commercialization teams are welcome to connect during BIO Partnering at JPM.
KLUS Pharma also seeks innovative projects in early discovery stages.
Business Development Team
KLUS Pharma Inc.
Cranbury, New Jersey, USA